Table 3.
Prevalence of cardiovascular events in non-drug naive and drug-naive T2DM patients at the beginning of the study
| Cardiovascular events | Group 1 (non-drug naive) |
Group 2 (drug-naive) |
p |
|---|---|---|---|
| N = 978 | N = 221 | ||
| Acute myocardial infarction (yes/no) | 17/961 (1.4%) | 0/221 (0%) | 0.2 |
| Stroke (yes/no) | 37/941 (3.7%) | 4/217 (1.8%) | 0.1 |
| Cardiac catheterization (yes/no) | 39/939 (4.0%) | 1/220 (0.4%) | < 0.01 |
| Coronary revascularization (yes/no) | 32/946 (3.9%) | 0/221(0%) | < 0.05 |
| Heart failure (yes/no) | 29/949 (2.9%) | 1/220 (0.4%) | < 0.05 |
| Angina pectoris (yes/no) | 48/930 (4.9%) | 0/221 (0%) | < 0.01 |
| Atrial fibrillation (yes/no) | 2/976 (0.2%) | 0/221 (0%) | 0.5 |
Group 1 Individuals with T2DM undergoing drug treatment, Group 2 Newly diagnosed drug-naive (< 3 months) patients with T2DM. Statistical significance was set at p < 0.05